Release date: 2015-04-15
Medtronic Co., Ltd. (NYSE: MDT) today announced the completion of its acquisition of Sophono, a privately held, developer and manufacturer of innovative magnetic hearing implant devices located in Boulder, Colorado, USA. This acquisition helps the Medtronic ENT business continue to focus on innovative therapies and innovative technology solutions that are in line with Medtronic's therapeutic innovation development strategy. The specific terms involved in the merger were not disclosed.
“As a market leader in ENT products and therapies, Medtronic is pleased to have Sophono's minimally invasive, stable hearing implant device that broadens our otology portfolio,†Medtronic Senior Vice President, Restorative Therapy Group Mr. Mark Fletcher, President of Surgery Technology, a subsidiary: "This acquisition allows us to work with more doctors around the world to help more patients have better hearing."
Sphono's magnetic bone conduction hearing implant devices are available in 42 countries and regions, and more than 4,000 patients have been implanted. This therapy is indicated for patients with unilateral deafness who are 5 years of age and older, or patients with conductive or mixed hearing loss. This slender, magnetic percutaneous Alpha 2MPO? sound processor enables otolaryngology and hearing specialists to help patients recover their hearing through a simple minimally invasive intervention. Sophono's groundbreaking technology, transcutaneous energy delivery (TET?), makes it the only optimized subcutaneous hearing system on the market today, where hearing is transmitted through the skin. Alpha2MPO allows patients to improve their hearing without worrying about potential skin complications caused by percutaneous puncture techniques based on bridge-based technology.
In several recent studies, the Sophono device was used to significantly improve the ability of both patients with conductive, mixed hearing loss or unilateral deafness to hear and recognize. At the 2015 Ultimate Colorado Midwinter Meeting in Vail, Colorado, USA, a preliminary study of clinical studies involving multiple devices showed that Alpha 2 MPO performed better in high-audio than percutaneous and transcutaneous conduction technologies on the market today. it is good.
According to the World Health Organization, 360 million people worldwide suffer hearing loss. In the United States alone, there are approximately 48 million patients with hearing impairment.
Medtronic will include the Sophono product line in the surgical technology business unit of the Restorative Therapy Group. The transaction is expected to be in line with Medtronic's long-term financial strategy and will not affect the financial year's earnings!
About Medtronic Surgical Technology
Medtronic's surgical technology business provides products and surgical solutions for surgical procedures in ENT, neurosurgery, spine surgery, orthopedics and oncology surgery. The business unit designs, develops, and manufactures surgical navigation and imaging technologies, surgical power equipment and systems, intraoperative neuromonitoring devices, advanced energy platform cutting and electrocoagulation systems, and implantable hydrocephalus drainage devices, while providing medical services. Provide relevant support.
Source: Bio-Exploration
Jelly Glue,Jelly Gelatin For Woodworking,High Viscosity Jelly Glue,Industrial Jelly Glue
Hebei Haodong Biological Technology Co.,Ltd. , https://www.hdgelatin.com